Deutsche starts Jazz with Buy into period of value creation

As previously reported, Deutsche Bank analyst David Hoang initiated coverage of Jazz Pharmaceuticals (JAZZ) with a Buy rating and $152 price target The firm attributes the recent pullback to macro developments, including President Trump’s threat of pharma tariffs and Most Favored Nation pricing, given that Jazz is an Irish-domiciled company. However, Deutsche believes the stock’s valuation discount is not warranted. Jazz is entering a period of value creation through the second half of 2027, with expansion of its oncology business and “resilience” of the neuroscience business, which should translate to growth, the analyst tells investors in a research note.